| Announcement of Regulatory Submission for Mirabegron (YM178), a Treatment for Overactive Bladder |
|
28/09/2011 14:53 (245 Day 02:19 minutes ago) | |||||
|
The FINANCIAL -- Tokyo, August 29, 2011 - Astellas Pharma Inc. today announced the submission of a New Drug Application and Market Authorisation Application for mirabegron (generic name / code name: YM178) to the U.S. Food and Drug Administration and the European Medicines Agency.
The submissions were sent on August 24 and 26, 2011 (Europe and US, respectively). Astellas is seeking approval for this first in a new class of medicine for the indication of overactive bladder (OAB*) associated with symptoms of urgency, urinary frequency, and urge urinary incontinence. Mirabegron is a once daily oral selective β3-adrenoceptor agonist discovered and developed by Astellas.
The pivotal Phase 3 clinical trials in the U.S. and Europe met primary endpoints compared to placebo. Astellas has been developing mirabegron as a global project. In Japan, Astellas was granted marketing approval under the trade name of Betanis® tablet in July 2011. Additionally, there is an on-going multiregional Phase 3 study in China, Korea, Taiwan, and India.
Astellas markets the OAB medication solifenacin succinate (known as VESIcare) in **67 countries/areas and has contributed to improving OAB associated symptoms.
|
|
|
